Kowa's Pemafibrate Granted Breakthrough Therapy Status by FDA

Kowa Company Ltd., based in Nagoya, Japan, has announced that its drug "K-808" (pemafibrate) has received Breakthrough Therapy designation from the U.S. FDA for treating primary biliary cholangitis (PBC). This designation aims to expedite the development and review process for drugs showing substantial improvements over existing treatments.

The decision was based on preliminary data from an ongoing Phase II clinical trial that indicated significant improvement, particularly in reducing alkaline phosphatase levels. Results were shared at the EASL Congress in May 2026.

Kowa is pursuing global approval of K-808, either in combination with ursodeoxycholic acid (UDCA) for those with an inadequate UDCA response, or as a monotherapy for those intolerant to UDCA. Kowa aims to enhance treatment options for PBC, a severe autoimmune liver disease that primarily affects women.